Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Inclusion Criteria: * Histologically or cytologically confirmed Carcinosarcoma (MMMT) * Measurable disease; * Only one prior systemic treatments after primary adjuvant treatment for persistent or metastatic disease are permitted, * Radiation therapy (adjuvant or palliative) must be completed ≥ 4 weeks prior to registration * Required laboratory values obtained =\< 7 days prior to registration: * Absolute Neutrophil Count (ANC) \>= 1500/mm\^3 * Platelets \>= 75,000/mm\^3 * Hemoglobin \>= 9.0 g/dL * Direct bilirubin =\< 1.5 x upper limit of normal (ULN) * Alkaline phosphatase =\< 2.5 x ULN (≤ 5 x ULN if liver metastasis is present) * SGOT(AST) =\< 2.5 x ULN (≤ 5 x ULN if liver metastasis is present) * Creatinine =\< 1.5 x ULN * Fasting serum cholesterol ≤ 350mg/dL (9.0 mmol/L) * Triglycerides ≤ 1.5 x ULN * Patients with Triglyceride levels \> 1.5 x ULN can be started on lipid lowering agents and reevaluated within 1 week; if levels go to ≤ 1.5 x ULN, they can be considered for the trial and continue the lipid lowering agents * International Normalized Ratio (INR) ≤ 1.5 (unless the patient is on full dose warfarin) * ECOG Performance Status (PS) 0-1 * Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent * Full-dose anticoagulants, if a patient is receiving full-dose anticoagulants, the following criteria should be met for enrollment: * The subject must have an in-range INR (usually betwee…